FIRST-308
The first phase 3 trial for patients whose bile duct cancer has outgrown the existing FGFR drugs.
Global, randomised; primary endpoint PFS. First US patient dosed 2025.
Setting
FGFR-altered cholangiocarcinoma refractory to chemotherapy and a first-generation FGFR inhibitor: tinengotinib vs FOLFOX/FOLFIRI
Phase
Phase 3
Sponsor
TransThera
Pages like this
not linked directly; found by shared links- CompanyTransThera Sciences
Shares Tinengotinib, Biliary tract cancer (cholangiocarcinoma).
- TermFGFR2 fusions and rearrangements
Shares Tinengotinib, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- TrialFIGHT-202
- TrialFOENIX-CCA2
- TermIntrahepatic, perihilar, distal and gallbladder cancer
- IdeactDNA-guided switching among FGFR inhibitors
Shares Tinengotinib, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- ProductPemigatinib
- ProductFutibatinib